S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
How High Can Copper Go? (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
How High Can Copper Go? (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
Could trawler cams help save world's dwindling fish stocks?
How High Can Copper Go? (Ad)
Southwest Airlines brings back dividend as travel rebounds
3 Dividend Kings With Royally Good Upside
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
How High Can Copper Go? (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
How High Can Copper Go? (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
Could trawler cams help save world's dwindling fish stocks?
How High Can Copper Go? (Ad)
Southwest Airlines brings back dividend as travel rebounds
3 Dividend Kings With Royally Good Upside
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
How High Can Copper Go? (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
How High Can Copper Go? (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
Could trawler cams help save world's dwindling fish stocks?
How High Can Copper Go? (Ad)
Southwest Airlines brings back dividend as travel rebounds
3 Dividend Kings With Royally Good Upside
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
How High Can Copper Go? (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
How High Can Copper Go? (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
Could trawler cams help save world's dwindling fish stocks?
How High Can Copper Go? (Ad)
Southwest Airlines brings back dividend as travel rebounds
3 Dividend Kings With Royally Good Upside
NASDAQ:EKSO

Ekso Bionics - EKSO Stock Forecast, Price & News

$1.27
-0.06 (-4.50%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.27
$1.37
50-Day Range
$1.04
$1.70
52-Week Range
$1.03
$3.49
Volume
43,613 shs
Average Volume
50,808 shs
Market Capitalization
$16.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Ekso Bionics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
607.2% Upside
$9.00 Price Target
Short Interest
Healthy
0.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.11mentions of Ekso Bionics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$33,677 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.04) to ($0.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

255th out of 1,027 stocks

General Industrial Machinery, Industry

3rd out of 11 stocks

EKSO stock logo

About Ekso Bionics (NASDAQ:EKSO) Stock

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.

Receive EKSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter.

EKSO Stock News Headlines

Ekso Bionics Reports Third Quarter 2022 Results
Preview: Ekso Bionics Holdings's Earnings
Ekso Bionics Holdings, Inc. (EKSO)
See More Headlines
Receive EKSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter.

EKSO Company Calendar

Last Earnings
11/01/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
General industrial machinery,
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EKSO
Previous Symbol
OTCMKTS:EKSOD
Employees
55
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+607.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-9,760,000.00
Net Margins
-109.88%
Pretax Margin
-109.88%

Debt

Sales & Book Value

Annual Sales
$11.25 million
Book Value
$2.94 per share

Miscellaneous

Free Float
12,741,000
Market Cap
$16.72 million
Optionable
Not Optionable
Beta
1.59

Key Executives

  • Mr. Steven A. Sherman (Age 76)
    Chairman & CEO
    Comp: $100k
  • Mr. Scott W. Davis (Age 52)
    Pres & COO
  • Mr. Jerome Wong (Age 48)
    Corp. Controller, Corp. Sec. & CFO
  • Ms. Rachael Anderson
    Global Director of Marketing & Strategic Growth
  • Mr. Anthony Pratt
    VP of Sales
  • Ms. Ann Cookson
    HR Director
  • Ms. Foon Lim Chwee
    Pres of APAC
  • Mr. Jason C. Jones
    Sr. VP of Product Devel.
  • Mr. Stephan Aderhold
    Sr. VP & GM of EMEA













EKSO Stock - Frequently Asked Questions

Should I buy or sell Ekso Bionics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EKSO shares.
View EKSO analyst ratings
or view top-rated stocks.

What is Ekso Bionics' stock price forecast for 2023?

1 analysts have issued 12-month price objectives for Ekso Bionics' stock. Their EKSO share price forecasts range from $9.00 to $9.00. On average, they expect the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 607.2% from the stock's current price.
View analysts price targets for EKSO
or view top-rated stocks among Wall Street analysts.

How have EKSO shares performed in 2022?

Ekso Bionics' stock was trading at $2.65 at the beginning of the year. Since then, EKSO stock has decreased by 52.0% and is now trading at $1.2726.
View the best growth stocks for 2022 here
.

Are investors shorting Ekso Bionics?

Ekso Bionics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 49,000 shares, a decrease of 20.3% from the October 31st total of 61,500 shares. Based on an average daily trading volume, of 30,100 shares, the short-interest ratio is presently 1.6 days. Approximately 0.4% of the shares of the stock are sold short.
View Ekso Bionics' Short Interest
.

When is Ekso Bionics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our EKSO earnings forecast
.

How were Ekso Bionics' earnings last quarter?

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) announced its quarterly earnings data on Monday, November, 1st. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.10. The firm had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.58 million. Ekso Bionics had a negative net margin of 109.88% and a negative trailing twelve-month return on equity of 45.07%. During the same period last year, the business posted ($0.52) earnings per share.

When did Ekso Bionics' stock split?

Ekso Bionics shares reverse split on the morning of Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Ekso Bionics own?
What is Ekso Bionics' stock symbol?

Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."

Who are Ekso Bionics' major shareholders?

Ekso Bionics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (2.43%), Citadel Advisors LLC (0.00%), Strategic Wealth Investment Group LLC (0.17%) and Dimensional Fund Advisors LP (0.14%). Insiders that own company stock include Jason C Jones, Jerome Wong, John Glenn, Scott G Davis and Steven Sherman.
View institutional ownership trends
.

How do I buy shares of Ekso Bionics?

Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ekso Bionics' stock price today?

One share of EKSO stock can currently be purchased for approximately $1.27.

How much money does Ekso Bionics make?

Ekso Bionics (NASDAQ:EKSO) has a market capitalization of $16.72 million and generates $11.25 million in revenue each year. The company earns $-9,760,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.

How can I contact Ekso Bionics?

Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The official website for the company is www.eksobionics.com. The company can be reached via phone at (510) 984-1761, via email at investors@eksobionics.com, or via fax at 510-927-2647.

This page (NASDAQ:EKSO) was last updated on 12/8/2022 by MarketBeat.com Staff